89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients

Authors list

Sietske BM Gaykema Carolien P Schröder Joanna Vitfell-Rasmussen Sue Chua Thijs H Oude Munnink Adrienne H Brouwers Alfons HH Bongaerts Mikhail Akimov Cristina Fernandez-Ibarra Marjolijn N Lub-de Hooge Elisabeth GE de Vries Charles Swanton Udai Banerji
Scroll for detail on labs, facilities & authors

Abstract

HSP90 chaperones have key client proteins that are involved in all hallmarks of breast cancer growth and progression. The primary aim of this clinical trial was to evaluate the feasibility of using (89)Zr-trastuzumab PET (for HER2-positive breast cancer) or (89)Zr-bevacizumab PET [for estrogen receptor (ER)-positive breast cancer] to determine in vivo degradation of client proteins caused by the novel HSP90 inhibitor NVP-AUY922.

Journal details

Journal Clinical cancer research
Volume 20
Issue number 15
Pages 3945-3954
Publication date

Full text links

Publisher website (DOI) 10.1158/1078-0432.ccr-14-0491
Europe PubMed Central 25085789
Pubmed 25085789

Keywords

Type of publication